Phase II Study of Pazopanib and Paclitaxel in Patients With Refractory Urothelial Cancer

The combination of paclitaxel and pazopanib resulted in a promising ORR of 54% in patients with advanced pretreated UC. This represents a greater response rate and median survival than found with other existing second-line regimens for UC and is worthy of further study.